ReviewChembiochem : a European journal of chemical biology2026
Synthetic Ligands of Myeloid C-Type Lectin Receptors.
Review in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
C-type lectin receptors (CLRs) are one of the major classes of pattern recognition receptors. They mediate numerous biological events, including cell adhesion, pathogen recognition, and innate immune responses. Initial recognition of a pathogen by specific CLRs shapes the inflammatory landscape of the host, and the resulting immune response can be protective but can also contribute to immune-mediated pathology. Understanding the binding of CLRs to their ligands has gained increasing attention and triggered research in the fields of structural biology, pathogen recognition, and immune signaling. Of critical importance for understanding the factors that affect binding and, therefore, being able to therapeutically exploit CLRs as druggable targets, is the identification of binding epitopes and drug-like analogs. Hence, informed tailoring of candidate molecules can enhance affinities, exploit avidity, and enable the design of novel ligands. This review surveys the extensive diversity that has been generated in the area of synthetic myeloid CLR ligands, focusing on the dendritic cell-specific ICAM3-grabbing non-integrin receptor (DC-SIGN), macrophage-inducible C-type lectin (Mincle), dendritic cell-associated C-type lectin-1 (Dectin-1), and langerin. Context is rendered via the description of binding modes, signaling pathways, and therapeutic opportunities, which facilitates the identification of current limitations and potential future directions of the field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.